Overview:
In order to estimate the current size of the human microbiome market, this study involved four major activities. A thorough investigation was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, hypotheses, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to estimate the overall market size. Subsequently, methods for data triangulation and market breakdown were employed to estimate the market size of various segments.
DRIVER: Collaborative efforts between microbiome industry and academia for microbiome research
To progress microbiome research, the academic community and the microbiome industry have formed cooperative efforts. In order to understand the intricate relationships between microbes and their hosts, this collaboration makes use of the knowledge and resources of both industries. While academia offers cutting-edge research, scientific rigor, and a diversity of academic perspectives, industry contributes significant funding, technological advancements, and access to large-scale datasets. Together, they quicken the process of gaining new understanding of the function of the microbiome in health and illness, opening the door to creative treatments, diagnostics, and personalized medicine strategies. This cooperative strategy creates a mutually beneficial relationship that advances science and facilitates the practical application of microbiome research.
RESTRAINT: Adverse impact of complex regulatory policies on commercialization of microbiomes
The commercialization of microbiomes may be negatively impacted by intricate regulatory policies. Navigating regulatory frameworks presents special challenges for microbiome research due to its dynamic and rapidly evolving nature. Protracted approval procedures, exorbitant expenses, and exacting specifications may impede the prompt creation and introduction of microbiome-driven products and treatments.
Small and medium-sized businesses (SMEs) and startups are disproportionately affected by these barriers, which make it harder for them to compete with more established, larger businesses. Additionally, inconsistent laws in various nations or regions can obstruct access to international markets and hinder commercialization efforts even more. To encourage innovation and guarantee the responsible and effective commercialization of microbiome-based technologies, regulatory bodies and industry stakeholders must work together to streamline and harmonize regulatory policies, promote clear guidelines, and foster collaboration.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904
Revenue Growth Dynamics:
The global human microbiome market in terms of revenue was estimated to be worth $0.3 billion in 2023 and is poised to reach $1.7 billion by 2029, growing at a CAGR of 36.1% from 2023 to 2029.
Data Triangulation:
Following the completion of the market size estimation process, the entire market was divided into multiple segments. Data triangulation and market breakdown procedures were used when appropriate to finish the entire market engineering process and obtain precise statistics for every segment. Through an analysis of numerous variables and patterns from the supply and demand sides, the data was triangulated.
Market Definition:
The term "human microbiome" describes a group of microorganisms that reside on and within the human body, such as bacteria, viruses, fungi, and other microbes. These microbes have intricate and dynamic interactions with both the human host and one another. They are crucial to many physiological processes, such as metabolism, immunological response, and digestion. The microbiome of humans is extremely varied and differs amongst people and bodily parts. The market consists of a number of industries, such as consumer goods, diagnostics, treatments, and research tools, all of which are focused on using the microbiome's potential and knowledge to enhance human health and wellbeing. This covers the creation of diagnostic tools for evaluating and tracking the microbiome as well as the development and marketing of microbiome-based treatments, such as live biotherapeutic products (LBPs), probiotics, prebiotics, and other microbial interventions.
Geographical Growth Scenario:
Asia Pacific is the human microbiome market's fastest-growing region.
Due in large part to growing demand for personalized medicine, advances in sequencing technologies, and growing recognition of the role of the microbiome in health and disease, the Asia Pacific human microbiome market is anticipated to grow at the highest CAGR during the forecast period. Due to the growing emphasis on personalized medicine and preventative healthcare, which is fueling the demand for human microbiomes, the Asian market has also attracted a lot of attention from international players.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904
Global Key Players:
The market for human microbiome is highly consolidated, with key players strategizing to capture the market. Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc. (US), YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).
Recent Developments:
# In November 2021, Seres Therapeutics collaborated with Bacthera to manufacture SER-109. The company is a leading manufacturer for recurrent Clostridioides difficile infection (rCDI). As per the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of LBPs located on Lonza’s Ibex campus in Visp, Switzerland.
# In June 2020, Enterome announced a new financing totaling $52.6million to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.
# In July 2020, OptiBiotix Health PLC launched WellBiome, a revolutionary ingredient to support digestive, cardiovascular, and metabolic health.
No comments:
Post a Comment